To evaluate the potential role of iNKT activation in MDSC control, EG7 tumour-bearing mice were treated with αGalCer (Fig. 7d) leading to an increase in iNKT cell frequency in the tumours and spleens (Fig. 7e), and associated IFN-γ release into the serum (Supp Fig. 7g), with a reduction in the MDSCs in these tissues (Fig. 7f). The gene discussed is IFNG; the disease is neoplasm.